ROG.SW Roche Holding AG (SIX) Jan 26 2026 Pre-Mkt: Earnings in focus, CHF347.90
The ROG.SW stock opens pre-market with Roche Holding AG priced at CHF347.90 on the SIX exchange in Switzerland as investors eye the earnings release due on 29 Jan 2026. Volume is 876,097 shares and the 50-day average sits at CHF322.19. Early moves will hinge on guidance and Genentech manufacturing updates after recent site investments and approvals.
Earnings outlook and timeline for ROG.SW stock
Roche reports earnings on 29 Jan 2026, making this a true earnings spotlight for ROG.SW stock. Analysts will focus on EPS trends versus EPS CHF11.72 and margin pressure after last year’s net income decline of 28.01%. Expect management comments on product launches, pricing in Switzerland, and 2026 revenue guidance to drive the pre-market session.
Recent catalysts and ROG.SW stock news
Two near-term catalysts matter: Genentech’s larger Holly Springs investment and new FDA approvals for Lunsumio VELO. Both support Roche’s mid-term growth narrative and diagnostics demand. Read the market summary on MarketWatch and corporate detail on StockAnalysis for the latest moves MarketWatch StockAnalysis.
Financials and valuation metrics for ROG.SW stock
Roche shows robust cash generation with free cash flow per share CHF15.68 and dividend per share CHF9.70. Current PE on the quote is 29.70 and dividend yield is 2.79%. Price-to-book sits near 9.74 and enterprise value to EBITDA is 24.33, indicating premium valuation versus healthcare peers whose average PE is 34.52 in Switzerland’s sector data.
Technical and trading view for ROG.SW stock
On the charts ROG.SW stock reads overbought with RSI 73.06 and ADX 43.57 indicating a strong trend. Day range is CHF344.50–348.70 and year range CHF231.90–349.70. Average volume is 1,142,773; today’s trade of 876,097 implies relative volume 0.72, so liquidity is normal for a pre-market session.
Meyka AI grade and model outlook for ROG.SW stock
Meyka AI rates ROG.SW with a score out of 100: 69.21 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The model highlights strong cash flow but flags valuation and higher leverage metrics versus peer medians. Use this grade as a data point, not investment advice.
Risks and opportunity for ROG.SW stock investors
Key opportunities include Genentech manufacturing expansion and diagnostics rollouts in China. Main risks are Swiss pricing pressure after U.S. drug pricing deals and a high price/book at 9.74 that could amplify downside if guidance disappoints. Consider exposure size, dividend yield, and diversified healthcare allocation when trading into earnings.
Final Thoughts
Key takeaway: ROG.SW stock opens pre-market at CHF347.90 with earnings on 29 Jan 2026 and several operational catalysts on the table. Meyka AI’s forecast model projects a monthly level of CHF346.58, implying a -0.38% move versus the current price. The model’s yearly projection of CHF242.82 implies -30.18% downside, reflecting a conservative medium-term view. These forecasts contrast with technical overbought signals, creating a mixed risk-reward into the report. Our view: treat earnings as a volatility event. If management confirms growth drivers, target a near-term range CHF320.00–CHF380.00; if guidance weakens, downside may test CHF280.00. Forecasts are model-based projections and not guarantees. Meyka AI provides this as AI-powered market analysis for clarity ahead of the print.
FAQs
When does Roche report earnings and how will it affect ROG.SW stock
Roche reports on 29 Jan 2026. Earnings will affect ROG.SW stock through EPS progress, guidance, and commentary on pricing and production. Expect higher intraday volatility and a focus on Genentech updates that may shift investor sentiment.
What are the key valuation metrics to watch for ROG.SW stock
Watch PE 29.70, price-to-book 9.74, and free cash flow per share CHF15.68. These metrics signal a premium valuation for ROG.SW stock and will shape market reaction if growth guidance misses expectations.
What is Meyka AI’s grade for ROG.SW stock and what does it mean
Meyka AI rates ROG.SW with a score out of 100: 69.21 | Grade: B | Suggestion: HOLD. The grade balances cash flow strength, sector context, and valuation. It is informational and not investment advice.
How should investors approach ROG.SW stock before earnings
Approach ROG.SW stock with defined risk limits and position sizing. Use options or stop limits for earnings risk. Focus on guidance cues and consider the dividend yield 2.79% if holding through volatility.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
